AC Immune (NASDAQ:ACIU) Upgraded at Zacks Research

Zacks Research upgraded shares of AC Immune (NASDAQ:ACIU) from a strong sell rating to a hold rating in a research report sent to investors on Tuesday morning,Zacks.com reports.

ACIU has been the subject of several other reports. BTIG Research reissued a “buy” rating and set a $8.00 price objective on shares of AC Immune in a report on Monday. Wall Street Zen upgraded shares of AC Immune from a “hold” rating to a “buy” rating in a research report on Tuesday, May 13th. Two analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, AC Immune currently has an average rating of “Moderate Buy” and an average target price of $10.00.

AC Immune Stock Performance

Shares of AC Immune stock opened at $2.38 on Tuesday. The stock has a market capitalization of $238.98 million, a PE ratio of -4.10 and a beta of 1.61. AC Immune has a 52-week low of $1.43 and a 52-week high of $3.98. The company has a 50-day simple moving average of $2.16 and a two-hundred day simple moving average of $1.98.

AC Immune (NASDAQ:ACIU) last released its quarterly earnings data on Tuesday, August 5th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.05). AC Immune had a negative net margin of 174.94% and a negative return on equity of 49.35%. The company had revenue of $1.65 million for the quarter, compared to analysts’ expectations of $1.98 million. As a group, equities research analysts forecast that AC Immune will post -0.62 EPS for the current fiscal year.

Hedge Funds Weigh In On AC Immune

Institutional investors have recently bought and sold shares of the business. Two Sigma Advisers LP bought a new position in AC Immune during the fourth quarter valued at $36,000. Jane Street Group LLC purchased a new stake in shares of AC Immune in the fourth quarter valued at $66,000. Sei Investments Co. purchased a new stake in shares of AC Immune in the second quarter valued at $51,000. Banque Cantonale Vaudoise purchased a new stake in shares of AC Immune in the first quarter valued at $50,000. Finally, Squarepoint Ops LLC purchased a new stake in shares of AC Immune in the fourth quarter valued at $118,000. Institutional investors own 51.36% of the company’s stock.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.